Tổ leọ nửừ tham gia trong caực nghieõn cửựu Tổ leọ nửừ tham gia trong caực nghieõn cửựu
hứ ứ tiõ hựtbố ttihứ ứ tiõ hựtbố tti
p
h
o
ứ
ng ngử
ứ
a
ti
e
õ
n p
h
a
ựt

b
a
ố
ng s
t
a
ti
np
h
o
ứ
ng ngử
ứ
a

)
JUPITER : 38
,
2%
(
6801 /17.802
)
,( ),( )
JUPITER – Women Subgroup Data
Rosuvastatin Placebo
N (Rate
*
)N (Rate
*
) HR (95% CI) P-value
Women N=3426 N=3375
Primary endpoint** 39 (0.56) 70 (1.04) 0.54 (0.37-0.80) 0.002
Any MI 10 (0.14) 18 (0.27) 0.54 (0.25-1.18) 0.11
Any stroke 18 (0.26) 23 (0.34) 0.77 (0.42-1.42) 0.40
Arterial revascularisation 8 (0.12) 29 (0.43) 0.27 (0.12-0.59) 0.0003
Ail
li i
8 (0 12)
33 (0 49)
024(011
0 51)
0 0001
A
rter
i

51)
<
0
.
0001
MI, stroke or CV death 36 (0.52) 48 (0.71) 0.73 (0.48-1.13) 0.16
Men
N=5475
N=5526
Men
N=5475
N=5526
Primary endpoint** 103 (0.88) 181 (1.54) 0.58 (0.45-0.73) <0.0001
Any MI 21 (0.18) 50 (0.42) 0.42 (0.26-0.71) 0.006
Any stroke 15 (0.13) 41 (0.34) 0.37 (0.21-0.67) 0.0005
Arterial revascularisation 63 (0.54) 102 (0.86) 0.63 (0.46-0.86) 0.003
Arterial revascularisation or
hospitalisation for unstable angina
68 (0.58) 110 (0.93) 0.63 (0.46-0.85) 0.002
MI, stroke or CV death
47 (0.40)
109 (0.92)
0.44 (0.31
-
0.61)
<0.0001
* Rates are per 100 person-years
Mora S et al. Circulation 2010; 120; 1069-1077
MI,